Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Hepatocellular Carcinoma: early-phase trial registry
9 of 17 indexed Advanced Hepatocellular Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 9 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Advanced Hepatocellular Carcinoma: 17 US clinical trials tracked, 9 recruiting.
Advanced Hepatocellular Carcinoma is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition advanced-hepatocellular-carcinoma
OPEN 9 | RECR 53% | LATE 2 | EARLY 15 | RANK #1004 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenoid Cystic Carcinoma (53% recruiting · 17 trials)
Advanced Hepatocellular Carcinoma lists 9 open slots (53% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Hepatocellular Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Hepatocellular Carcinoma is recruiting above its size-band peers.
9 of 17 indexed trials (52.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Hepatocellular Carcinoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 2 of 17 trials (11.8%). 16 distinct sponsors appear on at least one study for this condition label.
-
Most Advanced Hepatocellular Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 17 trials that report a genuine target (sentinel values excluded). 11 of those (64.7%) plan for fewer than 100 participants.
-
Advanced Hepatocellular Carcinoma research is mostly interventional.
17 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
NCT07166406
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Iterion Therapeutics
NCT05797805
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
NCT06600321
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
National Cancer Institute (NCI)
NCT06811116
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
NCT06789848
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
NCT05092373
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Emory University
NCT07174570
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
University of Southern California
NCT05791448
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
Mary Feng, MD
NCT04430452
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
AstraZeneca
NCT05883644
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
NCT04514484
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Daiichi Sankyo
NCT01033240
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
H3 Biomedicine
NCT02834780
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
AbbVie (prior sponsor, Abbott)
NCT00517920
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Mayo Clinic
NCT05176223
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01356628
Siliphos in Advanced Hepatocellular Carcinoma
Abby Siegel
NCT01129570
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 7 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Hepatocellular Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Hepatocellular Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Hepatocellular Carcinoma page
17 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Advanced Hepatocellular Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Advanced Hepatocellular Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Hepatocellular Carcinoma condition card totals 17 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.